PRTC

Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia

Retrieved on: 
화요일, 6월 28, 2022
Health, Other Science, General Health, Clinical Trials, Research, Science, Biotechnology, Vedanta, Patient, Research, PRTC, Capsule, Death, Inflammatory Bowel Diseases, Texas Tech University College of Agricultural Sciences & Natural Resources, Cancer, CDI, Freeze-drying, Cell, LSE, Technology transfer, PureTech Health, Immune system, Bacteria, Risk, Liver disease, Library, Fermentation, Clinical trial, LBP, List of life sciences, CGMP, Microbiota, Clostridioides difficile infection, Temperature, Leadership, Biodiversity, Food allergy, Recurrence, Doctor of Philosophy, Pharmaceutical industry, Vaccine, Fine chemical, Science, Nature, Clostridioides

With this facility, Vedanta has CGMP capabilities from clinical development to commercial launch, underscoring its leadership in the discovery, development, and manufacture of drugs based on defined bacterial consortia.

Key Points: 
  • With this facility, Vedanta has CGMP capabilities from clinical development to commercial launch, underscoring its leadership in the discovery, development, and manufacture of drugs based on defined bacterial consortia.
  • Today, we have industrialized an end-to-end manufacturing process for this class of product candidates, at commercial scale, by solving an array of technical challenges related to CGMP production of defined bacterial consortia.
  • Vedanta believes it was the first company to manufacture CGMP-grade defined bacterial consortia in powdered form, which enables stable, consistent oral formulations.
  • This was the most advanced clinical trial of an investigational drug based on a defined bacterial consortium to date.

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

Retrieved on: 
화요일, 6월 14, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Hospital, IPF, Data, Death, PRTC, Șaeș, Fibrosis, Time, Pneumonia, Company, AES, COVID, Interstitial lung disease, Headache, Research, Keck School of Medicine of USC, Safety, Fatigue, Pirfenidone, LSE, Annual report, Degenerative disease, Long COVID, Nausea, Cancer, Inflammation, Environment, AE, Dizziness, Therapy, University, Daphne, Risk, FDA, Proning, COVID-19, Patient, Private Securities Litigation Reform Act, U.S. FDA, Medicine, Natural history, Incidence, Breast cancer–related regulator of tp53, SEC, Twitter, Population, Survivor, Drug development, Rash, Intention, Form 6-K, PureTech Health, Principal, Idiopathic pulmonary fibrosis, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in patients with post-acute Long COVID with respiratory complications.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in patients with post-acute Long COVID with respiratory complications.
  • The global, double-blind, randomized, placebo-controlled study is one of few to complete in patients with post-acute COVID.
  • The study enrolled 177 patients averaging 55 years of age who experienced continued respiratory complications following hospitalization for acute COVID-19 infection that required treatment with supplemental oxygen.
  • The primary efficacy endpoint was a three-month change from baseline compared to placebo on the six-minute walk test (6MWT) distance.

Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

Retrieved on: 
수요일, 6월 8, 2022
Health, Other Health, Other Science, General Health, Research, Science, Biotechnology, LBP, PRTC, Liver disease, Conference, Research, Lotte New York Palace Hotel, LSE, MSU MFA Program in Science & Natural History Filmmaking, Inflammatory Bowel Diseases, List of life sciences, Cell, Library, Doctor of Philosophy, Immune system, Food allergy, Bacteria, PureTech Health, Cancer, Pharmaceutical industry, Science, Nature

Vedanta Biosciences , a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held June 15-16, 2022 at the Lotte New York Palace in New York, NY.

Key Points: 
  • Vedanta Biosciences , a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held June 15-16, 2022 at the Lotte New York Palace in New York, NY.
  • Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks.
  • Vedanta Biosciences controls a foundational portfolio of more than 45 patents and has built what it believes is one of the largest libraries of bacteria derived from the human microbiome.
  • Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of the cross-talk between the microbiome and the immune system.

PureTech Founded Entity Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer

Retrieved on: 
월요일, 6월 6, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, People, Entrepreneurship, PRTC, Company, Research, Marketing, Government budget balance, COO, LSE, Annual report, Industrial and production engineering, Degenerative disease, Forward-looking statement, CEO, Cancer, Environment, Senior, Precision, University, Exact sciences, Therapy, Brain, FDA, Growth, Commercial, Patient, Private Securities Litigation Reform Act, Risk, U.S. FDA, Technology, COVID-19, The People's Operator, Franklin, Twitter, SEC, CMS, Industry, Medicine, Drug development, General manager, Form 6-K, PureTech Health, Foundation Medicine, Communication, Boston Scientific, Pharmaceutical industry, Management, Risk management, Medical device, Engineering, Northwestern University, Yolo Akili

Franklin brings more than two decades of experience across business, commercial and strategic marketing in the diagnostics, life sciences and technology industries leading and evolving innovation.

Key Points: 
  • Franklin brings more than two decades of experience across business, commercial and strategic marketing in the diagnostics, life sciences and technology industries leading and evolving innovation.
  • Most recently, Franklin served as General Manager of the Precision Oncology business unit at Exact Sciences.
  • Previously, Franklin was the Chief Commercial Officer at Thrive Earlier Detection Corp, where he led the go-to-market strategy development for their ground-breaking multi-cancer early detection assay.
  • June 6, 2022 Akili Interactive (Akili), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced that industry veteran Matt Franklin will join the company in the newly created role of President and Chief Operating Officer, effective June 21, 2022.

PureTech to Present at the Jefferies Healthcare Conference

Retrieved on: 
수요일, 6월 1, 2022
Health, FDA, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PRTC, Company, Conference, Research, LSE, Annual report, Degenerative disease, Cancer, Environment, Multimedia, Therapy, FDA, Private Securities Litigation Reform Act, U.S. FDA, SEC, Twitter, Drug development, Form 6-K, PureTech Health, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220601005456/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220601005456/en/
    PureTechs Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Legal & Operating Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022, at 9:30am EDT.
  • This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the Jefferies Healthcare Conference and our future prospects, developments and strategies.
  • These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future.

PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox

Retrieved on: 
목요일, 5월 26, 2022
Technology, FDA, Other Technology, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Data Management, Work, Cancer, Risk, Optimism, Company, Nausea, PureTech Health, Dizziness, Medicine, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Variable, Degenerative disease, Environment, Patient, Biology, LSE, RBLX, COVID-19, Aggression, Government budget balance, FDA, Research, Brain, Industry, U.S. FDA, Frustration, Creativity, Partnership, ADHD, Forward-looking statement, Communication, Test of Variables of Attention, Imagination, BIG, Therapy, Headache, Twitter, Emotion, 3D, SEC, Entrepreneurship, Axis, NYSE, PRTC, Attention deficit hyperactivity disorder predominantly inattentive, Annual report, CEO, Pharmaceutical industry, Yolo Akili, Roblox

Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients lives.

Key Points: 
  • Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients lives.
  • Akili has captured our imagination with its prescription treatment for children with ADHD delivered through an action video game experience and shares our vision and enthusiasm for whats possible through interactive, digital experiences.
  • Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients lives.
  • Initially, the companies will establish an exclusive Roblox rewards exchange tied to Akilis EndeavorRx treatment (see full indication below).

PureTech to Present at the UBS Global Healthcare Conference

Retrieved on: 
화요일, 5월 17, 2022
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Other Health, Cancer, Company, PureTech Health, Private Securities Litigation Reform Act, Degenerative disease, Environment, Multimedia, LSE, Form 6-K, Research, FDA, U.S. FDA, Conference, Drug development, Therapy, Twitter, SEC, PRTC, Annual report, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., Chief Financial Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2022, at 10:45am EDT.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., Chief Financial Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2022, at 10:45am EDT.
  • View the full release here: https://www.businesswire.com/news/home/20220517005373/en/
    PureTechs George Farmer, Chief Financial Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2022, at 10:45am EST.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the UBS Global Healthcare Conference and our future prospects, developments and strategies.
  • These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future.

PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022

Retrieved on: 
월요일, 5월 16, 2022
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Cancer, Physician, Inflammation, Pulmonary fibrosis, Company, PureTech Health, Ageing, Radiation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Food, International Conference on Cold Fusion, Survival, AES, Incidence, Idiopathic pulmonary fibrosis, AUC, Degenerative disease, Environment, Multimedia, Patient, Poster, LSE, Risk, Life expectancy, Form 6-K, Cmax, Pirfenidone, Research, Lymphedema, FDA, Breast cancer–related regulator of tp53, U.S. FDA, Fibrosis, Time, Conference, Compliance, Prognosis, Drug development, TID, Therapy, Twitter, American Thoracic Society, IPF, Fed, SEC, Diagnosis, COVID, PRTC, Innovation, Annual report, Pharmaceutical industry, Dietary supplement

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of additional data for PureTechs LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of additional data for PureTechs LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.
  • Key outcomes of this study that are supportive of the observed improved tolerability of LYT-100 were reported in January 2022.
  • View the full release here: https://www.businesswire.com/news/home/20220516005130/en/
    PureTech today announced the presentation of additional data for PureTech's LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.
  • PureTech also expects to initiate registration-enabling studies of LYT-100 in patients with IPF in the first half of 2022.

PureTech Announces Share Buyback Program Update

Retrieved on: 
월요일, 5월 9, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Drug development, Common stock, Calendar, Account, Private Securities Litigation Reform Act, Twitter, Company, LSE, Jefferies, London, AGM, Treasury, Degenerative disease, PRTC, FDA, Annual report, Environment, Therapy, Form 6-K, Article, Financial Conduct Authority, Sale, Chapter 12, Title 11, United States Code, Share repurchase, London Stock Exchange, SEC, PureTech Health, Program, Research, Growth, Cancer, 5-1-1, BST, European Union (Withdrawal) Act 2018, U.S. FDA, Announcement, Pharmaceutical industry, Bank, Security (finance), EU

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that, in connection with the $50 million share buyback program announced on 5 May 2022, it is now commencing purchases of the Companys ordinary shares of one pence each (Ordinary Shares) (the Program).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that, in connection with the $50 million share buyback program announced on 5 May 2022, it is now commencing purchases of the Companys ordinary shares of one pence each (Ordinary Shares) (the Program).
  • Jefferies will make its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company.
  • PureTech will announce any market repurchases of Ordinary Shares no later than 7.30 a.m. BST on the business day following the calendar day on which the repurchase occurred.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including those related to the Companys share buyback program and any future purchases of its ordinary shares thereunder.

PureTech Announces Share Buyback Program of up to $50 Million

Retrieved on: 
목요일, 5월 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Board, Drug development, Board of directors, Account, Private Securities Litigation Reform Act, Twitter, PureTech Health, Company, LSE, FDA, Degenerative disease, PRTC, Annual report, Environment, Therapy, Share repurchase, SEC, Research, Cancer, Form 6-K, U.S. FDA, Announcement, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announces that its Board of Directors has approved a share buyback program in respect of its ordinary shares of one pence each (Ordinary Shares) up to a maximum consideration of $50 million (the Share Buyback Program).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announces that its Board of Directors has approved a share buyback program in respect of its ordinary shares of one pence each (Ordinary Shares) up to a maximum consideration of $50 million (the Share Buyback Program).
  • The Share Buyback Program follows consultation with shareholders and is consistent with PureTechs capital allocation strategy1 and stated approach to drive additional value for its shareholders.
  • The Company had consolidated cash and cash equivalents of $465.7 million and $413.2 million at December 31, 2021 and March 31, 2022, respectively.
  • Further details of the Share Buyback Program will follow.